MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
81.17
+0.15 (+0.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous close81.02
Open81.30
Bid81.02 x 800
Ask81.62 x 3200
Day's range81.11 - 81.94
52-week range58.03 - 83.85
Volume5,793,580
Avg. volume10,438,111
Market cap208.984B
Beta (3Y monthly)0.31
PE ratio (TTM)25.63
EPS (TTM)3.17
Earnings date30 Jul 2019
Forward dividend & yield2.20 (2.80%)
Ex-dividend date2019-03-14
1y target est88.07
  • Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
    Zacks3 days ago

    Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

    Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

  • Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
    Zacks3 days ago

    Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates

    Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.

  • Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
    Zacks3 days ago

    Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

    The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.

  • Synlogic (SYBX) Enters Cancer Collaboration with Roche
    Zacks4 days ago

    Synlogic (SYBX) Enters Cancer Collaboration with Roche

    Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

  • J&J's Invokana sNDA Gets Priority Review Status From FDA
    Zacks4 days ago

    J&J's Invokana sNDA Gets Priority Review Status From FDA

    FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes

  • Reuters4 days ago

    UPDATE 2-U.N. creates new Ebola chief role to tackle security, political issues in Congo

    The United Nations named an Emergency Ebola Response Coordinator on Thursday, a new position to boost efforts to contain a 10-month epidemic in the Democratic Republic of Congo that has killed 1,241 people and is spreading. The drive to rein in the deadly virus has been hampered by attacks on treatment centers by armed groups operating in Congo’s lawless east and by distrust among residents, many of whom view the disease as a conspiracy.

  • Array BioPharma Gains on Colorectal Cancer Study Success
    Zacks5 days ago

    Array BioPharma Gains on Colorectal Cancer Study Success

    Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.

  • Reuters5 days ago

    Congo wants more use of Merck vaccine rather than J&J newcomer - minister

    Democratic Republic of Congo called on Wednesday for Merck's experimental Ebola vaccine to be fully licensed to facilitate its use in the Ebola-hit country, while saying Johnson & Johnson's rival drug would complicate matters. Both vaccines are experimental drugs that can be used under strictly controlled research protocols but Merck's has been used throughout the outbreak and has proven highly effective, the World Health Organization (WHO) says. Congolese Health Minister Oly Ilunga Kalenga told reporters in Geneva that the government would roll out a "geographic ring" vaccination strategy in the coming days.

  • Company News For May 22, 2019
    Zacks5 days ago

    Company News For May 22, 2019

    Companies In The News Are: KSS,AZO,HD,MRK

  • Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
    Zacks5 days ago

    Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

    Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.

  • Merck Foundation Announces Grant to American Cancer Society to Improve Access to Cancer Care in Resource-Limited Settings
    Business Wire5 days ago

    Merck Foundation Announces Grant to American Cancer Society to Improve Access to Cancer Care in Resource-Limited Settings

    The Merck Foundation (the Foundation) and the American Cancer Society (ACS) announced today that the Foundation awarded a $1.99 million, five-year grant to ACS to improve support and access to care for people living with cancer in low-and-middle-income countries, particularly in sub-Saharan Africa. This funding will help ACS further develop its capacity development approach to expanding patient navigation to countries with a growing burden of cancer. More than 70% of the 9 million cancer-related deaths worldwide are in resource-limited settings, where patients face many barriers in seeking a timely diagnosis and receiving high-quality cancer care.

  • Barrons.com6 days ago

    Merck Snaps Up Cancer Drugmaker Peloton Therapeutics

    American pharmaceutical giant Merck & Co. said it is buying Peloton Therapeutics, a clinical-stage biopharmaceutical company, for $1.05 billion in cash.

  • Merck buys Peloton to expand its kidney cancer treatment portfolio
    Reuters6 days ago

    Merck buys Peloton to expand its kidney cancer treatment portfolio

    The acquisition can strengthen Merck's presence in the field of renal cell carcinoma and bolster its cancer drug portfolio. Merck's blockbuster immunotherapy Keytruda was approved last month in the United States for treating renal cell cancer. Peloton has a drug that looks promising in renal cell carcinoma, and there's actually been a lot of success in the field in recent years," said Brad Loncar, who runs the Loncar Cancer Immunotherapy ETF.

  • Merck's Keytruda Fails in Late-Stage Breast Cancer Study
    Zacks6 days ago

    Merck's Keytruda Fails in Late-Stage Breast Cancer Study

    Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.

  • Business Wire6 days ago

    Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

    Merck (MRK), known as MSD outside the United States and Canada, and Peloton Therapeutics, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma (RCC).

  • Investing.com6 days ago

    Stocks - Kohls, JC Penny, Tesla Fall Premarket; Boeing Rises

    Investing.com - Stocks in focus in premarket trading on Tuesday:

  • Business Wire7 days ago

    Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer

    Merck , known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy .

  • Associated Press7 days ago

    Supreme Court sends dispute over Fosamax back to lower court

    The Supreme Court said Monday that a judge must decide whether a dispute between drugmaker Merck and patients who alleged they were injured by its bone-strengthening drug Fosamax can go forward. Users of Fosamax, which is prescribed to treat osteoporosis in women who have gone through menopause, had sued arguing that Merck had failed to provide adequate warnings of a specific risk of bone fracture on the drug's label. The Supreme Court did not answer whether the case should move forward.

  • Reuters7 days ago

    UPDATE 3-U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits

    The U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation. The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision to let the lawsuits proceed even though the Food and Drug Administration had rebuffed Merck when the company sought to add a warning to Fosamax's label about fracture risk.

  • Why Merck (MRK) is a Great Dividend Stock Right Now
    Zacks7 days ago

    Why Merck (MRK) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

  • AbbVie's Brain Cancer Candidate Fails in Phase III Study
    Zacks7 days ago

    AbbVie's Brain Cancer Candidate Fails in Phase III Study

    AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

  • Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
    Zacks10 days ago

    Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

    FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

  • Reuters10 days ago

    ANALYSIS-Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles

    Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk. Some legal experts believe Bayer will have a tough time convincing appellate courts to throw out verdicts and lawsuits on those grounds. Bayer has a better shot if a business-friendly U.S. Supreme Court takes up the case, experts said.

  • ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
    Zacks11 days ago

    ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

    FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.